Pfizer Inc at Goldman Sachs Global Healthcare Conference Transcript
Welcome to our session here at the Goldman Sachs Healthcare Conference. I'll have to let Keira know that we observe that 8-hour, 5-minute time difference between here and London. We're super pleased here to have Pfizer join us. My name is Chris Shibutani. I'm a member of the Goldman Sachs research team covering pharmaceuticals and biotechnology. Pfizer here is strongly represented by the tour de force the R&D group, Mikael Dolsten, who's been heading up that effort for many years now. And the newest member of the team, Dr. William Pao, welcome.
And I think it will be as an introduction. I think many of us are familiar with Mikael, but give you a chance to sort of tell us a little bit about your story, your background. I know you're coming over from pRED at Roche, a little bit of shift in sort of like the stage of things that you're looking at. Give us a sense for what your background and what your mission is, why you're the right guy for Albert to tap you as he continues to shape the C-suite?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
